卵巢癌免疫治疗：机遇、进展与挑战。
Ovarian cancer immunotherapy: opportunities, progresses and challenges.
机构信息
Department of Immunology, University of Connecticut School of Medicine, Farmington, USA.
出版信息
J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7.
Abstract
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
摘要
由于侵袭性卵巢癌的生存率较低，因此迫切需要新的有效治疗方法。有令人信服的证据表明，针对卵巢癌的免疫反应可能在控制这种疾病方面发挥重要作用。我们在此总结了多种已被提出并针对晚期卵巢癌进行潜在治疗益处测试的基于免疫的策略。我们将研究一个有效的针对卵巢癌的治疗性疫苗不仅可用于诱导疾病缓解，而且还可用于预防疾病复发这一前提的证据。我们还将突出卵巢癌疫苗开发中的问题和挑战，并批判性地讨论一些现有的免疫治疗策略的局限性。最后，我们将总结我们在使用患者特异性肿瘤衍生热休克蛋白肽复合物治疗晚期卵巢癌方面的经验。
相似文献
1
Ovarian cancer immunotherapy: opportunities, progresses and challenges.卵巢癌免疫治疗：机遇、进展与挑战。
J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7.
2
Immunotherapy in ovarian cancer.卵巢癌的免疫疗法。
Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.
3
Ovarian cancer: designing effective vaccines and specific diagnostic tools.卵巢癌：设计有效的疫苗和特异性诊断工具。
Immunotherapy. 2014;6(1):35-41. doi: 10.2217/imt.13.144.
4
Immunity and immune suppression in human ovarian cancer.人卵巢癌中的免疫与免疫抑制。
Immunotherapy. 2011 Apr;3(4):539-56. doi: 10.2217/imt.11.20.
5
Emerging immunotherapies in ovarian cancer.卵巢癌中的新兴免疫疗法。
Discov Med. 2015 Sep;20(109):97-109.
6
Opportunities in immunotherapy of ovarian cancer.卵巢癌免疫治疗的机遇
Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i11-i15. doi: 10.1093/annonc/mdw084.
7
Targeted immune therapy of ovarian cancer.卵巢癌的靶向免疫治疗
Cancer Metastasis Rev. 2015 Mar;34(1):53-74. doi: 10.1007/s10555-014-9540-2.
8
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.通过双特异性单克隆抗体重新靶向的自体T淋巴细胞进行腹腔内治疗使晚期卵巢癌消退。
J Natl Cancer Inst. 1995 Oct 4;87(19):1463-9. doi: 10.1093/jnci/87.19.1463.
9
Immunologic approaches to ovarian cancer treatment.卵巢癌治疗的免疫学方法。
J Clin Oncol. 2007 Jul 10;25(20):2884-93. doi: 10.1200/JCO.2007.11.0775.
10
Immunotherapy in Ovarian Cancer.卵巢癌的免疫疗法
Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5.
引用本文的文献
1
The Role of the Plasminogen Activator Inhibitor 1 ( ) in Ovarian Cancer: Mechanisms and Therapeutic Implications.纤溶酶原激活物抑制剂1（ ）在卵巢癌中的作用：机制及治疗意义
Glob Med Genet. 2024 Oct 29;11(4):358-365. doi: 10.1055/s-0044-1791734. eCollection 2024 Dec.
2
CD4CCR8 Tregs in ovarian cancer: a potential effector Tregs for immune regulation.CD4CCR8+Tregs 在卵巢癌中的作用：一种潜在的效应性 Tregs，可用于免疫调节。
J Transl Med. 2023 Nov 10;21(1):803. doi: 10.1186/s12967-023-04686-3.
3
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.癌症免疫编辑：实体瘤中的消除、平衡和免疫逃逸。
Exp Suppl. 2022;113:1-57. doi: 10.1007/978-3-030-91311-3_1.
4
Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.采用先进递送策略增强小分子和基于细胞的卵巢癌治疗药物递送
Adv Ther (Weinh). 2020 Nov;3(11). doi: 10.1002/adtp.202000144. Epub 2020 Aug 16.
5
microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.miRNA-1271-5p/TIAM1 通过抑制 Notch 信号通路抑制卵巢癌的进展。
J Ovarian Res. 2020 Sep 18;13(1):110. doi: 10.1186/s13048-020-00720-w.
6
MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer.miR-217 通过抑制卵巢癌细胞中白细胞介素-6 的分泌抑制 M2 样巨噬细胞极化。
Inflammation. 2019 Oct;42(5):1517-1529. doi: 10.1007/s10753-019-01004-2.
7
Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues.卵巢癌细胞中双链RNA模式识别受体信号的调节促进炎症信号。
Oncotarget. 2018 Nov 30;9(94):36666-36683. doi: 10.18632/oncotarget.26378.
8
Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.通过癌症和免疫生物标志物的组合提高癌症检测：一种建模方法。
J Transl Med. 2018 Mar 20;16(1):73. doi: 10.1186/s12967-018-1432-8.
9
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.放射治疗在增强妇科癌症免疫治疗活性中的潜在作用。
Cancer Manag Res. 2017 Oct 31;9:553-563. doi: 10.2147/CMAR.S116683. eCollection 2017.
10
The immunopeptidomic landscape of ovarian carcinomas.卵巢癌的免疫肽组学全景。
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1.
本文引用的文献
1
Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.不同分期上皮性卵巢癌患者血清中高丰度急性期蛋白的改变及其相关性表达。
J Hematol Oncol. 2009 Aug 27;2:37. doi: 10.1186/1756-8722-2-37.
2
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.一项关于粒细胞-巨噬细胞集落刺激因子、重组干扰素γ1b联合卡铂治疗复发、铂敏感型卵巢癌、输卵管癌及原发性腹膜癌的II期研究。
Gynecol Oncol. 2009 May;113(2):210-5. doi: 10.1016/j.ygyno.2009.02.007. Epub 2009 Mar 4.
3
Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis.热休克蛋白在感染介导的炎症诱导肿瘤发生中的作用。
J Hematol Oncol. 2009 Jan 30;2:5. doi: 10.1186/1756-8722-2-5.
4
5
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.辅助性自体治疗性疫苗（HSPPC-96；维特司班）对比单纯观察用于肾细胞癌肾切除术后复发高危患者：一项多中心、开放标签、随机III期试验
Lancet. 2008 Jul 12;372(9633):145-154. doi: 10.1016/S0140-6736(08)60697-2. Epub 2008 Jul 3.
6
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer.复发时的CA125变化速率是复发后生存的高度显著预测指标：一项针对晚期卵巢癌维持性奥瑞珠单抗免疫疗法的随机安慰剂对照研究的5年随访调查结果
J Immunother. 2008 Feb-Mar;31(2):207-14. doi: 10.1097/CJI.0b013e31816060ce.
7
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.NY-ESO-1b肽与蒙他尼德ISA-51对处于高危首次缓解期的上皮性卵巢癌患者进行疫苗接种的安全性和免疫原性研究。
Clin Cancer Res. 2008 May 1;14(9):2740-8. doi: 10.1158/1078-0432.CCR-07-4619.
8
Tumor escape mechanism governed by myeloid-derived suppressor cells.由髓系来源的抑制性细胞调控的肿瘤逃逸机制。
Cancer Res. 2008 Apr 15;68(8):2561-3. doi: 10.1158/0008-5472.CAN-07-6229.
9
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.转移性肾细胞癌患者接种自体肿瘤衍生的维特彭疫苗：临床研究结果
Br J Cancer. 2008 Apr 22;98(8):1336-41. doi: 10.1038/sj.bjc.6604266. Epub 2008 Mar 25.
10
Immunotherapy opportunities in ovarian cancer.卵巢癌的免疫治疗机遇
Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57. doi: 10.1586/14737140.8.2.243.
Zotero 插件